AccessibilityHelpAbout Us
American Oriental Bioengineering logo

American Oriental Bioengineering(OTC) AOBI

Market Cap$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2002)-100%
5 Year-100%
1 Year+2,500%
1 Month+983%
$0.01
+0.00%
+0.00Today
American Oriental Bioengineering last closing stock price
MetricPriceDate
Last closeUSD 0.012026-08-21
American Oriental Bioengineering stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.012026-08-13
1 month+983.33%USD 0.002026-06-22
3 month+983.33%USD 0.002026-05-22
Year to date+983.33%USD 0.002025-12-31
1 year+2,500%USD 0.002025-07-30
3 year+2,500%USD 0.002023-08-16
5 year-99.53%USD 2.752021-08-20
Since inception-100%USD 400.802002-06-27

American Oriental Bioengineering Financials at a Glance

Market Cap

$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$121.58M

Net Income (TTM)

-$91.02M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1026.43 (High)

Price

$0.01

Volume

4

Open

$0.01

Previous Close

$0.01

Daily Range

$0.01 - $0.01

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Mar 18, 2025

AOBI News

The 15 Most-Watched Personal Products Stocks

Dan DzombakAug 10, 2011

Wall Street's Best Hidden Stocks

Rich DupreyApr 26, 2011

The 15 Most-Watched Personal Products Stocks

Dan DzombakApr 8, 2011

3 Top Stocks at Half-Price

Rich DupreyApr 4, 2011

7 Reasons to Worry About Next Week

Rick MunarrizMar 11, 2011

The 5 Cheapest Stocks Right Now

Ilan MoscovitzFeb 24, 2011

Should You Sell American Oriental Bioengineering Right Now?

Jeremy PhillipsJan 25, 2011

3 Top Stocks at Half-Price

Rich DupreyJan 10, 2011
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About American Oriental Bioengineering

American Oriental Bioengineering, Inc. is a biotechnology company based in Beijing, China, specializing in the development, manufacturing, and commercialization of a diverse range of pharmaceutical and healthcare products. The company offers both prescription medications and over-the-counter solutions, targeting various health conditions.

Products and Services
  • Prescription medications including Shuanghuanglian Lyophilized Injection Powder for flu symptoms
  • Over-the-counter products like Cease Enuresis Patch for bedwetting management
  • Nutraceuticals, including soybean peptide-based beverages and supplements
Growth Outlook
  • Expansion in the Chinese healthcare market presents significant opportunities
  • Increasing demand for nutraceutical products aligns with health trends
  • Focus on innovative pharmaceutical solutions may enhance market position
Financial Highlights
  • Recent quarterly revenue of $17.94 million shows potential for recovery
  • Trailing twelve months (TTM) gross profit margin at 30.57% indicates operational efficiency
  • Current ratio of 0.90 suggests manageable short-term liabilities
American Oriental Bioengineering, Inc. operates in a competitive biotechnology sector, focusing on both traditional pharmaceuticals and emerging nutraceutical markets. The company's diverse product offerings cater to a wide range of health issues, from respiratory infections to menstrual discomfort. Recent financial data indicates a revenue of $17.94 million for the latest quarter, reflecting a potential rebound in sales. The gross profit margin of 30.57% demonstrates the company's ability to maintain operational efficiency despite challenges. With a current ratio of 0.90, the company appears to be managing its short-term liabilities effectively, which is crucial for sustaining operations and pursuing growth opportunities. The overall outlook for American Oriental Bioengineering, Inc. remains positive, driven by market expansion and a commitment to innovation in healthcare solutions.
AI Generated • Aug 24, 2026

Industry

Personal Products

Sector

Consumer Staples

Headquarters

Beijing, BE 100176, CN

AOBI Financials

Key Financial Metrics (TTM)

Gross Margin

30.57%

Operating Margin

-37.89%

Net Income Margin

-41.15%

Return on Equity

-16.84%

Return on Capital

-13.91%

Return on Assets

-13.38%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

73.00K

Volume

4

Avg. Volume

3.635

Financials (TTM)

Gross Profit

$39.62M

Operating Income

-$78.14M

EBITDA

-$71.39M

Operating Cash Flow

-$31.24M

Capital Expenditure

-$28.41M

Free Cash Flow

-$59.65M

Cash & ST Invst.

$3.23M

Total Debt

$92.77M

American Oriental Bioengineering Performance Analysis

American Oriental Bioengineering sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42012-12-31111.6%
Q12013-03-31-66.3%
Q22013-06-30-3.7%
Q32013-09-30-11.3%
American Oriental Bioengineering sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42012-12-31-293.9%
Q12013-03-3140.6%
Q22013-06-3038.9%
Q32013-09-30-64.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2013YOY CHG

Revenue

$17.94M

-39.2%

Gross Profit

$3.11M

-51.9%

Gross Margin

17.33%

N/A

Market Cap

$900.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$0.24

N/A

Employees

3,719

N/A

Net Income

-$21.18M

-210.8%

EBITDA

-$16.01M

+2.6%

Quarterly Fundamentals

Name
Q3 2013YOY CHG

Total Cash

$3.23M

-87.8%

Total Debt

$92.77M

+38.0%

Accounts Receivable

$27.25M

-40.6%

Inventory

$20.52M

-25.5%

Long Term Debt

$5.06M

+786.0%

Short Term Debt

$87.71M

+31.6%

Return on Assets

-13.38%

N/A

Return on Invested Capital

-16.16%

N/A

Free Cash Flow

-$30.80M

-647.0%

Operating Cash Flow

-$17.05M

-531.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LGBICannabiz Mobile, Inc.
$0.00+0.00%
PARDPoniard Pharmaceuticals, Inc.
$0.00+0.00%
NEXINexImmune, Inc.
$0.00+0.00%
CDXICardax, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$147.55-0.04%
INTCIntel
$106.24+0.02%
NOKNokia
$10.76+0.01%
NVDANvidia
$223.67-0.01%

Questions About AOBI

What is the current price of American Oriental Bioengineering?

American Oriental Bioengineering is trading at $0.01 per share.

What is the 52-week range for American Oriental Bioengineering?

Over the past 52 weeks, American Oriental Bioengineering has traded between $0.00 and $0.01.

How much debt does American Oriental Bioengineering have?

American Oriental Bioengineering total debt is unavailable.

How much cash does American Oriental Bioengineering have on hand?

American Oriental Bioengineering does not have cash on hand data available.

What is American Oriental Bioengineering’s dividend yield?

American Oriental Bioengineering does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services